If, as Sillazze says, the company is going to be in a position 'to formulate a realistic evaluation of the company' after the FDA meeting, then the undisclosed indications must surely come hard on the back of the FDA meeting announcement. (With Angelman and PWS in competition, I fully expect the new indications to be without rivals which will increase their value)
I wouldn't be surprised to see 2 quick announcements followed by a presentation explaining it ALL.
I, for one, will be hanging on every word Jon says if it pans out the way I think it will.
PS The FDA meeting might see the new boss of Acadia saying something about Fragile X trials for 2591 if we are lucky.
If, as Sillazze says, the company is going to be in a position...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |